These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
459 related articles for article (PubMed ID: 26553611)
1. Molecular profiling of 6,892 colorectal cancer samples suggests different possible treatment options specific to metastatic sites. El-Deiry WS; Vijayvergia N; Xiu J; Scicchitano A; Lim B; Yee NS; Harvey HA; Gatalica Z; Reddy S Cancer Biol Ther; 2015; 16(12):1726-37. PubMed ID: 26553611 [TBL] [Abstract][Full Text] [Related]
2. Tumor profiling of gastric and esophageal carcinoma reveal different treatment options. Miura JT; Xiu J; Thomas J; George B; Carron BR; Tsai S; Johnston FM; Turaga KK; Gamblin TC Cancer Biol Ther; 2015; 16(5):764-9. PubMed ID: 25778705 [TBL] [Abstract][Full Text] [Related]
3. Potential actionable targets in appendiceal cancer detected by immunohistochemistry, fluorescent in situ hybridization, and mutational analysis. Borazanci E; Millis SZ; Kimbrough J; Doll N; Von Hoff D; Ramanathan RK J Gastrointest Oncol; 2017 Feb; 8(1):164-172. PubMed ID: 28280620 [TBL] [Abstract][Full Text] [Related]
4. BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis. Cremolini C; Di Bartolomeo M; Amatu A; Antoniotti C; Moretto R; Berenato R; Perrone F; Tamborini E; Aprile G; Lonardi S; Sartore-Bianchi A; Fontanini G; Milione M; Lauricella C; Siena S; Falcone A; de Braud F; Loupakis F; Pietrantonio F Ann Oncol; 2015 Oct; 26(10):2092-7. PubMed ID: 26153495 [TBL] [Abstract][Full Text] [Related]
5. Associations between primary tumor RAS, BRAF and PIK3CA mutation status and metastatic site in patients with chemo-resistant metastatic colorectal cancer. Christensen TD; Palshof JA; Larsen FO; Poulsen TS; Høgdall E; Pfeiffer P; Jensen BV; Yilmaz MK; Nielsen D Acta Oncol; 2018 Aug; 57(8):1057-1062. PubMed ID: 29380640 [TBL] [Abstract][Full Text] [Related]
8. The survival outcome of patients with metastatic colorectal cancer based on the site of metastases and the impact of molecular markers and site of primary cancer on metastatic pattern. Prasanna T; Karapetis CS; Roder D; Tie J; Padbury R; Price T; Wong R; Shapiro J; Nott L; Lee M; Chua YJ; Craft P; Piantadosi C; Sorich M; Gibbs P; Yip D Acta Oncol; 2018 Nov; 57(11):1438-1444. PubMed ID: 30035653 [TBL] [Abstract][Full Text] [Related]
9. Differential molecular markers of primary lung tumors and metastatic sites indicate different possible treatment selections in patients with metastatic lung adenocarcinoma. Deng LL; Deng HB; Lu CL; Gao G; Wang F; Yang Y Clin Transl Oncol; 2019 Feb; 21(2):197-205. PubMed ID: 29948972 [TBL] [Abstract][Full Text] [Related]
10. Molecular profiling of metastatic colorectal tumors using next-generation sequencing: a single-institution experience. Gong J; Cho M; Sy M; Salgia R; Fakih M Oncotarget; 2017 Jun; 8(26):42198-42213. PubMed ID: 28178681 [TBL] [Abstract][Full Text] [Related]
11. The gene mutational discrepancies between primary and paired metastatic colorectal carcinoma detected by next-generation sequencing. Zou SM; Li WH; Wang WM; Li WB; Shi SS; Ying JM; Lyu N J Cancer Res Clin Oncol; 2018 Nov; 144(11):2149-2159. PubMed ID: 30171333 [TBL] [Abstract][Full Text] [Related]
12. Utility of comprehensive genomic sequencing for detecting HER2-positive colorectal cancer. Shimada Y; Yagi R; Kameyama H; Nagahashi M; Ichikawa H; Tajima Y; Okamura T; Nakano M; Nakano M; Sato Y; Matsuzawa T; Sakata J; Kobayashi T; Nogami H; Maruyama S; Takii Y; Kawasaki T; Homma KI; Izutsu H; Kodama K; Ring JE; Protopopov A; Lyle S; Okuda S; Akazawa K; Wakai T Hum Pathol; 2017 Aug; 66():1-9. PubMed ID: 28235632 [TBL] [Abstract][Full Text] [Related]
13. Somatic mutation profiling and HER2 status in KRAS-positive Chinese colorectal cancer patients. Dong Z; Kong L; Wan Z; Zhu F; Zhong M; Lv Y; Zhao P; Shi H Sci Rep; 2019 Nov; 9(1):16894. PubMed ID: 31729406 [TBL] [Abstract][Full Text] [Related]
14. KRAS and BRAF mutational status in primary colorectal tumors and related metastatic sites: biological and clinical implications. Italiano A; Hostein I; Soubeyran I; Fabas T; Benchimol D; Evrard S; Gugenheim J; Becouarn Y; Brunet R; Fonck M; François E; Saint-Paul MC; Pedeutour F Ann Surg Oncol; 2010 May; 17(5):1429-34. PubMed ID: 20049644 [TBL] [Abstract][Full Text] [Related]
16. High concordance rate of KRAS/BRAF mutations and MSI-H between primary colorectal cancer and corresponding metastases. Fujiyoshi K; Yamamoto G; Takahashi A; Arai Y; Yamada M; Kakuta M; Yamaguchi K; Akagi Y; Nishimura Y; Sakamoto H; Akagi K Oncol Rep; 2017 Feb; 37(2):785-792. PubMed ID: 28000889 [TBL] [Abstract][Full Text] [Related]
17. Comparison of neuroendocrine differentiation and KRAS/NRAS/BRAF/PIK3CA/TP53 mutation status in primary and metastatic colorectal cancer. Kleist B; Kempa M; Novy M; Oberkanins C; Xu L; Li G; Loland C; Poetsch M Int J Clin Exp Pathol; 2014; 7(9):5927-39. PubMed ID: 25337237 [TBL] [Abstract][Full Text] [Related]
19. Genomic profiling of colorectal cancer in large-scale Chinese patients: amplification and somatic mutations in ERBB2. Liu Y; Bischof E; Chen Z; Zhou J; Zhang B; Zhang D; Gao Y; Quan M Oncol Res; 2024; 32(9):1429-1438. PubMed ID: 39220126 [TBL] [Abstract][Full Text] [Related]
20. BRAF, PIK3CA, and HER2 Oncogenic Alterations According to KRAS Mutation Status in Advanced Colorectal Cancers with Distant Metastasis. Nam SK; Yun S; Koh J; Kwak Y; Seo AN; Park KU; Kim DW; Kang SB; Kim WH; Lee HS PLoS One; 2016; 11(3):e0151865. PubMed ID: 26991109 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]